adagrasib
Sign in to saveAlso known as MRTX-849
Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer. Adagrasib is an inhibitor of G12C mutated KRAS GTPase. It is taken by mouth. It is being developed by Mirati Therapeutics.
Key facts
- Drug.image
- Adagrasib structure.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Krazati
- Drug.MedlinePlus
- a623003
- Drug.DailyMedID
- Adagrasib
- Drug.routes_of_administration
- By mouth
- Drug.class
- Antineoplastic agent
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- XX77
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 2326521-71-3
- Drug.PubChem
- 138611145
- Drug.DrugBank
- DB15568
- Drug.UNII
- 8EOO6HQF8Y
- Drug.KEGG
- D12301
- Drug.synonyms
- MRTX-849
- Drug.IUPAC_name
- {(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1methylpyrrolidin-2-yl]methoxy}-5,6,7,8tetrahydropyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop2-enoyl)piperazin-2-yl}acetonitrile
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 603.2524792600001
Show 4 more facts
- canonical SMILES
- CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F
- isomeric SMILES
- CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F
- Commons category
- Adagrasib
- chemical formula
- C₃₂H₃₅ClFN₇O₂
Sources (2)
via Wikidata · CC0
~5 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- History
- Society and culture
- Legal status
- References
- External links
{{Infobox drug | image = Adagrasib structure.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = | tradename = Krazati | Drugs.com = | MedlinePlus = a623003 | DailyMedID = Adagrasib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = Antineoplastic agent | ATC_prefix = L01 | ATC_suffix = XX77 | ATC_supplemental =
Excerpted from Wikipedia’s “adagrasib” article, available under the CC BY-SA 4.0 licence.